Bausch Health Companies Inc. (NYSE:BHC) Receives $7.42 Average Price Target from Brokerages

Shares of Bausch Health Companies Inc. (NYSE:BHC) have been given an average recommendation of “Reduce” by the seven brokerages that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and six have issued a hold recommendation on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $7.42.

BHC has been the topic of a number of research analyst reports. Jefferies Financial Group reiterated a “hold” rating and set a $8.00 target price (down previously from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th. StockNews.com upgraded Bausch Health Companies from a “hold” rating to a “buy” rating in a research note on Friday, October 25th. Finally, Royal Bank of Canada cut their target price on Bausch Health Companies from $11.00 to $10.00 and set a “sector perform” rating on the stock in a research note on Thursday, January 30th.

Bausch Health Companies Price Performance

BHC opened at $6.36 on Monday. The business has a 50 day simple moving average of $7.55 and a two-hundred day simple moving average of $7.45. The firm has a market capitalization of $2.30 billion, a price-to-earnings ratio of -13.25, a PEG ratio of 0.34 and a beta of 0.68. Bausch Health Companies has a one year low of $3.96 and a one year high of $11.46.

Hedge Funds Weigh In On Bausch Health Companies

A number of institutional investors have recently bought and sold shares of the stock. ExodusPoint Capital Management LP purchased a new stake in Bausch Health Companies in the 4th quarter worth $1,594,000. Cinctive Capital Management LP grew its position in shares of Bausch Health Companies by 165.6% during the fourth quarter. Cinctive Capital Management LP now owns 222,348 shares of the company’s stock valued at $1,792,000 after purchasing an additional 138,638 shares in the last quarter. Trexquant Investment LP grew its position in shares of Bausch Health Companies by 155.4% during the fourth quarter. Trexquant Investment LP now owns 298,334 shares of the company’s stock valued at $2,405,000 after purchasing an additional 181,532 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Bausch Health Companies by 12.5% during the fourth quarter. Geode Capital Management LLC now owns 715,570 shares of the company’s stock valued at $5,767,000 after purchasing an additional 79,488 shares in the last quarter. Finally, Franklin Resources Inc. grew its position in shares of Bausch Health Companies by 1.1% during the fourth quarter. Franklin Resources Inc. now owns 5,316,822 shares of the company’s stock valued at $42,855,000 after purchasing an additional 56,446 shares in the last quarter. 78.65% of the stock is owned by institutional investors.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.